Screening for Autism Spectrum Disorders

MAUREEN GRISsom, PhD, and MATTHEW TIFFANY, MD, Hofstra North Shore–Long Island Jewish Health System Family Medicine Residency at Southside Hospital, Bay Shore, New York
LAURIE DAVIDSON, MLis, MEd, Dahlgren Memorial Library at Georgetown University Medical Center, Washington, District of Columbia

Clinical Inquiries provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries Network (FPIN). Members of the network select questions based on their relevance to family medicine. Answers are drawn from an approved set of evidence-based resources and undergo peer review. The strength of recommendations and the level of evidence for individual studies are rated using criteria developed by the Evidence-Based Medicine Working Group (http://www.cebm.net/?o=1025). The complete database of evidence-based questions and answers is copyrighted by FPIN. If interested in submitting questions or writing answers for this series, go to http://www.fpin.org or e-mail: questions@fpin.org.

A collection of FPIN’s Clinical Inquiries published in AFP is available at http://www.aafp.org/afp/fpin.

Clinical Question
What is the best tool to screen young children for autism spectrum disorders (ASDs)?

Evidence-Based Answer
There are no studies directly comparing the various screening tools. The Modified Checklist for Autism in Toddlers (M-CHAT) is the tool most commonly used by physicians, followed by the Checklist for Autism in Toddlers (CHAT). All other tools account for about 3% of usage.

The M-CHAT should be used during routine well visits to screen low-risk children because of its positive predictive value (PPV) of approximately 60% when combined with follow-up for negative responses. (Strength of Recommendation [SOR]: A, based on a systematic review of cohort studies.) The CHAT, which has a PPV of 29% to 83% in low-risk children, can also be used. (SOR: B, based on a systematic review of multiple cohort studies of variable quality.) Several other screening tools are available; however, most have not been thoroughly evaluated for use in the general pediatric population.

Evidence Summary
There are no studies comparing ASD screening tools used in the same group of children.1 An online survey of 408 U.S. pediatricians across six states found that 90% of those who screened for ASDs used the M-CHAT, and 6.3% used the CHAT.2 Two other screening tools were used by less than 2% of pediatricians. The study was limited to the geographic areas surveyed and by its response rate of only 10%.

A systematic review included four cohort studies (N > 15,000 children) that evaluated the M-CHAT in screening for ASDs in low-risk children (defined as those screened during a routine visit, not in response to specific concerns or family history).1 The M-CHAT consists of 23 questions that the caregiver answers about the child’s behavior. The M-CHAT/F is a structured follow-up interview for negative responses to questions. For instance, a negative response to the question “Does your child ever pretend, for example, to talk on the phone or take care of a doll or pretend other things?” is followed up, and credit may be given for activities such as pushing a car on a pretend road. Negative responses on two critical items or three total items indicate that the child is at risk of ASDs and should be referred for further evaluation. In most trials, the M-CHAT was administered at 18 or 24 months of age. Without follow-up, the PPV ranged from 6% to 36%; the addition of the M-CHAT/F increased the PPV to 28% to 68%.1 A subsequent study of approximately 19,000 children reported a PPV of 6% for the M-CHAT alone and 54% for the M-CHAT/F.3

The same systematic review included five cohort studies (N = approximately 54,000 children) that evaluated the CHAT in screening for ASDs in low-risk children.1 The CHAT consists of nine questions for caregivers about the child’s behavior and a 10- to 15-minute clinical examination. Investigators in three of the trials administered the CHAT at 18 to 19 months of age and performed follow-up evaluations at 2.5 to 7 years of age. The PPV for the CHAT ranged from 29% to 83%. The studies varied in design, outcomes that were reported, and criteria for a positive screen. Of the two other tools noted in the survey,2 the
Pervasive Developmental Disorders Screening Tool has not been extensively evaluated, and the Childhood Autism Rating Scale is more commonly used in children who are at increased risk of ASDs.\(^4\)

**Recommendations from Others**

The American Academy of Pediatrics Council on Children with Disabilities recommends screening all children for autism at 18 and 24 months using a validated autism screening tool, but it does not recommend a specific tool.\(^5\)

Copyright Family Physicians Inquiries Network. Used with permission.

Address correspondence to Maureen Grissom, PhD, at mgrissom@nshs.edu. Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations.

---

**REFERENCES**


---

The secret to reaching your retirement goals — small, manageable steps. **With AXA.**

Retirement is about having the time and resources to experience the aspects of life that you enjoy most. Helping you to work towards having the income necessary is our job. AXA can take some of the concerns out of planning by helping you break down your goals into small, manageable steps. It’s what we do — so that you may continue focusing on what you do.

AXA offers a broad selection of retirement solutions to assist you in saving now in order to provide yourself with retirement income in the future. Want to learn more? Contact a Retirement Program Specialist for a complimentary consultation.

---

Visit us at booth #1926 during the AAFP Scientific Assembly, or

E-mail: connection@axa.us.com

Phone: (800) 523-1125, Option 3, Ext. 6263

Website: www.axa2plan.com